IndustryCompany release

Mentari Therapeutics reports $63.0M nine-month net loss, backed by related-party note

🇺🇸 InMed Pharmaceuticals Inc. (INM) · Mon 16 Nov 2026

Unaudited Q3 2026 statements show a $32.2M quarterly loss, $45.8M in cash and a roughly $50M note from a related party.

Mentari Therapeutics has reported a net loss of $32.2 million for the third quarter of 2026 and $63.0 million for the nine months ended 30 September 2026. The figures come from unaudited financial statements, so they could change when the numbers are finalised.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗

Article written by VigiEye from the official source (InMed Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →